Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAV, acid, Actemra, Alexion, ALI, arachidonic, AUD, Avigen, BARDA, biobehavioral, Biohaven, Biomedical, Biopharma, cancel, cardiopulmonary, cellular, chlorine, Clene, concept, contemplated, countermeasure, cycle, Denovo, Division, etesevimab, fenebrutinib, fewest, fifteen, gas, Genzyme, GlaxoSmithKline, GmbH, hepatocellular, ill, Kazia, kg, Kintara, Laminar, Leasehold, lethality, MCM, mild, molnupiravir, murine, neural, nirmatrelvir, ovine, PAXLOVID, permeability, ponesimod, Ponvory, poster, prepayment, Psychiatry, reclassified, ReDIRECT, refunded, Repurposing, revert, Ridgeback, ritonavir, scan, Secretary, sheep, sotrovimab, spend, sublicensing, substantive, tocilizumab, tolebrutinib, tract, twelve, vector, week, weighing
Filing tables
Filing exhibits
MNOV similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
MediciNova, Inc.
La Jolla, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (Nos. 333-252592, 333-233201 and 333-208274) and Form S-8 (Nos. 333-232239, 333-219491, 333-190490, 333-151808, 333-141694 and 333-122665) of MediciNova, Inc. of our report dated February 16, 2022, relating to the consolidated financial statements, which appears in this Form 10-K.
/s/ BDO USA, LLP
San Diego, California
February 16, 2022